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Mid-life hypertension and cerebral hypoperfusion may be preclinical abnormalities in people who later 
develop Alzheimer’s disease (AD). Although accumulation of amyloid-beta (Aβ) is characteristic of AD and 
is associated with upregulation of the vasoconstrictor peptide endothelin-1 (EDN1) within the brain, it is 
unclear how this affects systemic arterial pressure. We have investigated whether infusion of Aβ40 into 
ventricular cerebrospinal fluid (CSF) modulates blood pressure in the Dahl salt-sensitive rat. The Dahl 
salt-sensitive rat develops hypertension if given a high-salt diet. Intracerebroventricular infusion of Aβ 
induced a progressive rise in blood pressure (BP) in rats with pre-existing hypertension produced by a 
high-salt diet (P < 0.0001), but no change in BP in normotensive rats. The elevation in arterial pressure in 
high-salt rats was associated with an increase in low frequency spectral density in systolic blood 
pressure, suggesting autonomic imbalance, and reduced cardiac baroreflex gain. Our results demonstrate 
the potential for intracerebral Aβ to exacerbate hypertension, through modulation of autonomic activity. 
Present findings raise the possibility that mid-life hypertension in people who subsequently develop AD 
may in some cases be a physiological response to reduced cerebral perfusion complicating the 
accumulation of Aβ within the brain.  
 




Hypertension affects at least one quarter of adults and more than half of those over 60 years.1 It is a major 
risk factor for cognitive decline and vascular dementia (VaD)2 and has been reported to increase the risk 
of developing Alzheimer’s disease (AD)3, 4 but the mechanisms are unclear. Cerebrovascular changes in 
AD include disruption to the blood-brain barrier (BBB), endothelial dysfunction, arterial stiffness and 
cerebral amyloid angiopathy (CAA).5-7 Inadequate cerebral perfusion is an early-stage manifestation of 
AD and probably contributes to concomitant white matter pathology and cognitive decline.8-13 Recent 
studies in humans implicate cerebrovascular hypotension as a driver of systemic hypertension as a 
mechanism to preserve cerebral blood flow.14 
The identification of mid-life hypertension and cerebral hypoperfusion as preclinical abnormalities 
in people who later develop AD provides a potential opportunity for intervention to delay or slow disease. 
However, it remains unclear how the vascular and neurodegenerative processes interact. Studies in 
animal models suggest that hypertension and associated non-amyloid small vessel disease (SVD) may 
cause Aβ to accumulate within the brain.15-17 Retrospective analysis showed Aβ plaque load to be higher 
in post-mortem brain tissue from AD patients with than without a history of hypertension,18 supporting 
findings in animal models. 
However, the converse possibility should also be considered: that mid-life metabolic and structural 
cerebrovascular alterations in people who subsequently develop AD, may induce hypertension.14 In AD, 
intracerebral vascular tone, neurovascular coupling and autoregulation are disrupted by abnormalities 
that affect regulation of vascular calibre and reduce blood flow.9  These abnormalities include cholinergic 
deafferentation of cortical blood vessels,19 free radical-mediated cerebral vasoconstriction,20-23 Aβ-
mediated upregulation of endothelin-1 (EDN1) production,8, 24-26 and an increase in brain angiotensin II 
mediated at least partly by a rise in the activity of angiotensin-converting enzyme (ACE).27, 28 Maintenance 
of cerebral perfusion in the face of these metabolic abnormalities would require an increase in cerebral 
perfusion pressure, manifesting as systemic hypertension.29-31 
Ageing is associated with progressive decline in cardiovascular autonomic reflexes, particularly 
baroreflex sensitivity.32 The consequences can include increased BP variability, impaired responsiveness 
to challenges to BP, and an increased risk of sudden cardiac death. Altered baroreflex sensitivity is an 
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independent risk factor for the development of memory problems in older people.33 There is evidence of 
autonomic dysfunction in most types of dementia. It is particularly common in Parkinson’s disease 
dementia (PDD) and dementia with Lewy bodies (DLB), reflecting disruption to central autonomic 
pathways in the brain stem and hypothalamus. In AD, neurodegenerative changes affect autonomic 
nervous system pathways in the anterior cingulate, insular cortex and amygdala.34 Patients with Lewy 
body diseases, AD and VaD have an increased prevalence of orthostatic hypotension.  
Cardiovascular autonomic control mechanisms can be monitored by measurements of 
spontaneous fluctuations in heart rate and blood pressure, heart rate variability (HRV), systolic blood 
pressure variability (SBPV), and baroreflex gain (BRG) which provides information on the relative 
contribution of the baroreflex to control of heart rate. Impaired BRG may indicate cardiovascular or 
neurological disease. The baroreflex is essential for the short-term control of BP but may also influence 
BP over the longer term, although this is more controversial.35 
Aβ, in particular Aβ40, has been shown to induce vasoconstriction following topical application to 
isolated arteries36 or direct administration to mouse cortex.23 Application of Aβ40 but not Aβ42 to pial 
vessels impaired neurovascular coupling and reduced cerebral perfusion, replicating abnormalities of 
cerebral blood flow in a range of hAPP transgenic mouse models. Our aims in this study were to 
investigate whether intracerebroventricular (ICV) infusion of Aβ40 would induce hypertension, or 
augment hypertension in a hypertensive animal model. To manipulate these variables in vivo, we have 
used the Dahl salt-sensitive (DAHL/SS) rat in conjunction with intracerebroventricular (ICV) Aβ40 
infusion. Aβ42 aggregates too readily for sustained delivery by infusion pump, whereas Aβ40 is more 
soluble, is the major species of Aβ in human cerebrospinal fluid (CSF) and, as noted above, is known to 
induce the constriction of pial vessels that we wanted to model by ICV infusion. Our hypotheses were that 
Aβ40 would exacerbate systemic hypertension, with more pronounced effects in the presence of pre-
existing hypertension (high-salt DAHL/SS), and that the increase in blood pressure would be reflected in 





All experimental procedures in this study were conducted in strict accordance with the UK Animals 
(Scientific Procedures) Act 1986 and approved by University of Bristol local ethical review committee. 
The study used male Dahl salt-sensitive 12-14-week old rats (from Charles River, UK) with a mean initial 
weight of 360 g (range 303-416 g – for details see Table 1). DAHL/SS rats develop hypertension when fed 
a high-salt diet (8% NaCl), whereas DAHL/SS rats fed a low-salt diet (0.3% NaCl) have blood pressure 
within the normal range (systolic BP < 140 mmHg).37 DAHL/SS rats have other traits in common with 
many hypertensive humans, including insulin resistance, hyperlipidaemia with high serum cholesterol, 
and reduced renal function. Animals were fed a low-salt diet (0.3% NaCl) from weaning but half were 
subsequently preconditioned on a high-salt diet (8% NaCl) for 3 weeks prior to arrival. The two groups 
were fed these respective low- or high-salt diets throughout the study. Welfare assessments were 
conducted daily. The animals were housed at a constant 22°C under a 14:10 light/dark cycle with free 
access to food and water. Animals were initially accommodated in groups, before transfer to individual 
cages after implantation of the telemetry device. All data were analysed and are reported in accordance 
with ARRIVE guidelines.38  
Study Design 
Groups of 5 DAHL/SS rats were assigned to a low- or high-salt diet prior to arrival to our facility, 
according to a block randomization schedule determined by the supplier. Simple randomization was used 
to assign animals in each group to receive ICV infusion of saline or Aβ40. The Aβ infusion model does not 
fully reproduce the complex neuropathology of AD but does allow for the precise study of Aβ-specific, 
time course-dependent changes.39 A power calculation was performed to determine the minimum 
number (n = 6) of animals required for each experimental group; based on previous experience of similar 
studies, a conservative estimate of the standard deviation of mean blood pressure values (≤ 10%) was 
used, giving 80% power to detect changes of 12% or more at the p = 0.05 level and 90% power to detect 
differences of 15% or more. Male DAHL/SS were 12-14 weeks of age prior to telemetry surgery (see 
below), Specific Pathogen Free (barrier-maintained) and experiment-naïve.  
Experimental procedures 
Telemetry device implantation: 
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A telemetry system (Data Sciences International, MN, US) was used to record arterial pressure. The 
telemetry device was implanted according to the method of Waki et al.40 An aseptic laparotomy was 
performed under reversible general anaesthetic to expose the abdominal aorta. The catheter tip of a 
radio-telemetry device (PhysioTel® PA series transmitter model PA-C40) was implanted into the 
descending aorta and secured with tissue adhesive. The body of the device was placed in the abdominal 
cavity and secured to the abdominal wall during suture closure of the incision. After recovery from 
anaesthesia, rats were placed in individual cages on receiver platforms (PhysioTel® Receivers model 
RPC-1) connected to a CED1401 data acquisition interface and a computer running Spike2 software (both 
Cambridge Electronic Design, UK), enabling continuous acquisition of data. Baseline telemetry data 
collection was started 5 d after telemetry surgery and continued for 5-7 d, prior to mini-osmotic pump 
surgery.  
Mini-osmotic pump implantation:   
10-12 d after implantation of the telemetry device, a mini-osmotic pump was inserted for ICV infusion of 
Aβ40 or saline (control).39, 41 Prior to surgery, the mini-osmotic pump and vinyl catheter (Alzet® osmotic 
pump model 2004 and Alzet® brain infusion kit 1; Charles River) were filled under aseptic conditions 
with a solution containing either Aβ40 (1 mg/ml (231 µM) of stock solution prepared in 0.35% acetonitrile 
and diluted to the final concentration in sterile saline) or saline (with acetonitrile to the same final 
concentration). Under reversible general anaesthetic, the rat was placed in a stereotaxic frame and the 
skull exposed using aseptic surgical technique. The fine-gauge stainless steel cannula (brain infusion kit) 
was held in position by a clamp arm attached to the stereotaxic frame. The cannula was positioned and 
implanted below the skull surface into the right lateral ventricle (AP -1.0, L -1.6, D 5.0) and attached to the 
catheter and pump. The cannula was fixed in position and the mini-osmotic pump implanted 
subcutaneously. ICV osmotic infusion allowed continuous delivery of Aβ40 or saline at 0.25 µl per hour 
over a 4-week period (equivalent to 0.006 mg of Aβ40 per day). The rate of CSF production and removal in 
the rat is about 3.6 ml/d.42 The physiological level of Aβ40 in rat CSF is approximately 0.3-0.4 nM, so the 
addition of 0.006 mg/d Aβ40 should elevate this by approximately 1000-fold to 385 nM. However, Aβ40 is 
eliminated much more rapidly than the CSF itself,43 so we estimate the mean level to have been raised by 




Telemetry monitoring and data analysis: 
Rats were fitted with a telemetry device capable of measuring arterial pulse pressure. Heart rate (HR), 
respiratory rate (RR), systolic (SBP), diastolic (DBP) and mean blood pressure (MBP) were derived from 
this waveform using Spike2 software. The telemetry device was switched on 5 days after implantation to 
record for 5-7 days (baseline). Mean HR, RR, SBP, DBP and MBP were calculated for each 24-h period and 
an average baseline value for each parameter was determined. Following insertion of the ICV cannula, 
telemetry measurements were recorded at a digital sampling frequency of 100 Hz (low pass filter at 45 
Hz) continuously from 3-28 days post-surgery and the average for each 24-h period was determined 
relative to mean baseline values. 
HR and BP variability analysis 
Spike2 software was used for spectral analysis of HR and SBP variability (HRV and SBPV). These 
indicators of autonomic function were analysed by separating the main peaks of the power spectrum in 
the frequency domain using a Fourier transform algorithm (Supplementary Figure 6). The three main 
components of the power spectrum were interpolated at specific frequencies: very low frequency (VLF) 
fluctuations at 0-0.26 Hz; low frequency (LF) fluctuations at 0.26-0.76 Hz; and high frequency (HF) 
fluctuations at 0.76-3.3 Hz. VLF, LF and HF measurements were made in absolute values of HR power 
(bpm2/Hz) or SBP power (bpm2/Hz).40 
By use of Spike2 software, an index of baroreceptor sensitivity was derived from spontaneous 
fluctuations and pulse interval, according the time-series method of Oosting et al:44 (1) blood pressure 
and pulse interval traces are smoothed to minimize respiratory fluctuations; (2) episodes in which blood 
pressure rises or falls over several consecutive heartbeats (ramps) were identified; (3) ramp changes in 
blood pressure versus changes in pulse interval are plotted after delays of 3, 4 and 5 heartbeats; and (4) a 
linear best-fit of the relationship between changes in blood pressure and changes in pulse interval is 
calculated to estimate baroreceptor sensitivity, as described previously (Supplementary Figure 6).40 A 
mean r2 value > 0.7 for the three linear fits was used as a goodness-of-fit threshold, thereby excluding 
ramps with a poor straight-line fit. In younger adults with normal baroreflex function, no more than about 
30% of spontaneous SBP ramps are compensated for by a progressive reflex change in pulse interval.45 
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This physiological behaviour is explained by the fact that the sinus node is not under the exclusive control 
of the baroreflex.  
Tissue collection and preparation 
Brain tissue and plasma samples were collected post mortem. Tissue homogenates were separately 
prepared from anterior, intermediate and posterior regions of each cerebral hemisphere, yielding 6 
homogenates from each brain. Tissue was transferred to 2 mL screw-cap tubes with ceramic beads and 
1% SDS homogenization buffer (1% SDS, 10 mM Tris base pH 6, 0.1 mM NaCl, 1 µM PMSF, 1 µg/ml 
Aprotinin) at 20% w/v. Tissue was homogenized for 2 x 20 s at 6000 rpm in a Precellys® homogenizer 
(Bertin Technologies, from Stretton Scientific, UK) and centrifuged at 13000 rpm for 15 min at 4°C. 
Homogenates were aliquoted and stored at -80°C. Blood samples were collected by cardiac puncture 
under terminal anaesthesia in EDTA tubes and centrifuged immediately at 6000 rpm for 5 min. The 
plasma supernatant was collected and stored in aliquots at -80°C. Total protein was quantified in tissue 
and plasma samples by Coomassie (Bradford) protein assay (Thermo Scientific, UK).  
EDN1, Aβ40 and ECE-2 sandwich ELISAs 
EDN1 in plasma and brain homogenates was measured by sandwich ELISA using the Endothelin Pan 
Specific DuoSet ELISA kit (R&D Systems, UK). The recommended protocol was followed, with samples 
(diluted 1:4 in reagent diluent; 1% BSA in PBS, pH 7.2), standards (2-fold serial dilutions of EDN1 
standard, 0.98-250 pg/ml) and blanks (reagent diluent alone) added to the plate for 2 h. Aβ40 in plasma 
and brain homogenates was measured by sandwich ELISA, as described.46, 47 Samples homogenates (total 
protein 0.05 mg/ml) or plasma (1:2 dilution), blanks and a 7-point standard curve of recombinant Aβ40 
(0.2 – 12.5 nM; Sigma-Aldrich, UK), prepared in PBS containing 1% 1,10 phenanthroline. ECE-2 was 
measured by sandwich ELISA, modified from Palmer et al.24 Homogenate samples (1:2 dilution), blanks 
and seven serial dilutions of recombinant ECE-2 (R&D Systems) at 54.1 – 3460 ng/ml were added to wells 
in duplicate. For each assay, the bound antibody was detected with a 1:1 mixture of substrate solution 
(hydrogen peroxide and tetramethylbenzidine; R&D Systems) with 2N sulphuric acid to stop the reaction. 
The optical density was read at 450 nm (FLUOstar OPTIMA plate reader; BMG Labtech, Germany). To 
correct for any optical imperfections in the microplate, readings at 590 nm were subtracted from those at 
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450 nm. Sample concentrations of EDN1, Aβ40 and ECE-2 were interpolated from the respective standard 
curve. Each sample was assayed in duplicate. 
ECE-1 western blot 
ECE-1 was measured by western blot with a biotinylated ECE-1 antibody (BAF1784, R&D systems), as 
described.48 The antibody detects full-length ECE-1 at 120 kDa and a 75 kDa splice variant (ECE-1sv). 
Recombinant ECE-1 standard (1784ZN, R&D systems) was diluted to create a four-point standard curve 
(0.1 – 2.75 ng/µl) for each gel. Standards and samples of tissue homogenates (15 µg total protein) in SDS 
sample buffer were run on pre-cast gels before transfer to a nitrocellulose membrane. The primary 
antibody was added at 1:2000 in blocking buffer (3% BSA-TTBS) for 2 h. Streptavidin-conjugated 
peroxidase antibody was used for detection at 1:800 in blocking buffer. Each sample was measured in 
duplicate and the mean total ECE-1 + ECE-1sv concentration calculated. 
ACE activity 
ACE activity in brain homogenates and plasma was measured using the ACE1-specific fluorogenic 
substrate Abz-FRK(Dnp)-P (Biomol International) in the presence of the ACE-inhibitor, captopril (1 mM), 
as described by Miners et al.27, 28 ACE capture antibody (MAB929), recombinant ACE standard (929-ZN, 
R&D Systems) and fluorogenic substrate (ES005) were all from R&D Systems. Fluorescence (320/405nm) 
was measured after overnight incubation. ACE activity measurements were interpolated from the 
standard curve using a 4-parameter curve fit. 
Statistical Methods 
Statistical analyses were performed in GraphPad Prism 6. All data sets were assessed for normality of 
distribution by the D'Agostino & Pearson test. 
Baseline telemetry data (collected prior to mini-pump implantation) were log-transformed prior to 
analysis: the resultant parametric data were compared by unpaired samples t-test. Post-infusion 
telemetry data from each of the four sub-groups (low/high salt; Aβ/saline infusion) were compared by 
paired samples t-test to the respective baseline data. To compare the effects of Aβ and saline infusion, the 
telemetry data collected following infusion was adjusted relative to the corresponding sample pre-
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infusion baseline mean and analysed for each 24-hour period; best-fit regression lines (for change in 
physiological parameter over time post-infusion) were compared by sum-of-squares F-test. 




Mean baseline data are presented in Table 1. DAHL/SS rats fed the high-salt diet had significant (p < 
0.0001) hypertension at baseline (MBP (mean ± SEM): 151 ± 6 mmHg) compared to those on the low-salt 
diet (MBP: 114 ± 2 mmHg).  
Outcomes and Estimation 
High salt DAHL/SS telemetry post-infusion 
We compared the changes in HR, RR, MBP, SBP and DBP over baseline in Aβ- (n=6) and saline- (n=6) 
infused high-salt DAHL/SS rats from 3-28 d post-infusion (Supplementary Figure 1). BP increased over 
time in both saline- and Aβ-infused rats but the increase was markedly greater in the Aβ-infused animals. 
Comparison of best-fit regression lines by sum-of-squares F-test showed that the increases in MBP, SBP 
and DBP were much greater in Aβ-infused than saline-infused animals, and the decline in HR and RR less 
marked (p < 0.0001 for all five comparisons; Figure 1). The BP increase in the saline-infused group was 
accompanied by a drop in both HR and RR over time. The HR and RR of the Aβ-infused group did not 
change over the infusion period, despite the greater BP increase. In the final week following infusion 
(days 22-28 inclusive), MBP relative to pre-infusion baseline had increased by 21 ± 11 mmHg (mean ± 
SD) in the Aβ group (t (5) = 4.73, p = 0.005), compared to 11 ± 8 mmHg in the saline group (t (5) = 3.64, p 
= 0.015; Supplementary Figure 4 (A)). 
Low-salt DAHL/SS telemetry post-infusion 
We compared the changes in HR, RR, MBP, SBP and DBP with respect to baseline mean in Aβ- (n=8) and 
saline- (n=7) infused low-salt DAHL/SS rats (Supplementary Figure 2). Comparison of best-fit regression 
lines by sum-of-squares F-test revealed no differences in MBP, SBP or DBP between the Aβ- and saline-
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infused groups. Small but significant reductions were found in both HR and RR (P < 0.0001 for both) in 
the Aβ- compared to the saline-infused animals (Figure 2). MBP was marginally elevated by 3 ± 3 mmHg 
following Aβ infusion (days 22-28 mean vs. baseline mean; t (5) = 2.95, p = 0.022), but did not differ 
significantly after saline infusion (Supplementary Figure 4 (B)). This finding should be interpreted with 
caution as there was not a significant difference between Aβ- and saline-infusion by regression line 
comparison and the possibility of a type I statistical error cannot be excluded.  
Heart rate variability, systolic blood pressure variability and baroreflex gain in high-salt 
DAHL/SS post-infusion 
Data available for a subset of high-salt DAHL/SS (Aβ: n = 5; saline: n = 3) from 3-21 d post-infusion were 
analysed for HRV, SBPV and BRG (Supplementary Figure 3). A sum-of squares F-test comparison tested 
the null hypothesis (H0) that a single linear regression line could fit the combined data sets. We found no 
significant difference in the VLF (F2,148 = 0.120, ns) or LF component (F2,148 = 2.507, ns) of HRV (change in 
bpm2/Hz) between the saline- and Aβ-infused rats (H0 accepted; Figure 3 (A-B)). The HF component of 
HRV, reflecting respiration, increased over time in the saline group but remained at baseline in the Aβ40-
infusion group (F2,148 = 10.64, p < 0.0001; H0 rejected; Figure 3 (C)). A comparison of best-fit lines for the 
VLF, LF and HF components (mmHg2/Hz) of SBPV demonstrated that each increased significantly in the 
Aβ- compared to the saline-infusion group (VLF F2,148 = 17.46, LF: F2,148 = 15.59 both p<0.0001; HF: F2,148 = 
17.46 p<0.0005; H0 rejected; Figure 3 (D-F)).  
We compared the relative change in BRG over baseline in a subset of Aβ- (n = 5) and saline-infused 
(n = 3) high-salt DAHL/SS rats from 3-28 d post-infusion. There was a progressive decline in both positive 
(F2,202 = 28.91, p < 0.0001) and negative ramps (F2,202 = 4.761, p < 0.001) over the 28 days following Aβ40 
infusion but little change after saline infusion (H0 rejected; Figure 3 (G-H)). Comparison of best-fit 
regression lines showed that the data from the Aβ- and saline-infused groups differed significantly for 
both positive (p < 0.0001) and negative (p < 0.01) ramps, indicating a reduction in the sensitivity of the 
baroreflex response over time during Aβ infusion. 
Aβ40 level in brain tissue homogenates and plasma 
The level of Aβ40 (measured by sandwich ELISA) remaining in the brain after completion of the infusions 
was measured in homogenates of anterior, medial and posterior thirds of the left and right hemispheres. 
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We found no consistent differences between groups, either when comparing individual brain regions or 
when the measurements were combined to indicate the mean for each case (Supplementary Figure 5 (A)). 
Aβ40 is cleared quite rapidly from the CSF43, 49 and although there is some penetration of the brain 
parenchyma39 it does not aggregate to any significant extent.50 The finding that Aβ40 was not significantly 
elevated in the brain tissue of the rats that had received ICV infusion of Aβ is in keeping with these 
previous studies and suggests that infused Aβ peptide which may have penetrated the brain had been 
largely cleared from the brain by the time that the tissue was collected, i.e. after completion of the 4-
weeks of infusion.  
We also measured Aβ40 in plasma samples. The levels of peptide for several cases fell below the 
detection limit of the sandwich ELISA. No significant differences were found between the Aβ-infused 
groups in either the high salt or low salt DAHL/SS (Supplementary Figure 5 (B)). 
EDN1, ECE-1, ECE-2 and ACE activity 
We did not find significant differences between Aβ- and saline-infused rats in the level of EDN1, ECE-1, 
ECE-2 or ACE activity in brain homogenates, when either the mean values for the whole brain 
(Supplementary Figure 5 (C-F)) or the values for anterior, intermediate and posterior regions of each 
cerebral hemisphere (data not shown) were compared between subgroups. We also found no significant 
difference in ACE activity in plasma between Aβ- and saline-infused groups (Supplementary Figure 5 (G)). 
Adverse Events 
One animal from the high salt/Aβ40 infused group experienced a late failure of the aortic telemetry 
implant, 3 weeks after infusion surgery. 
Discussion 
In this study, we investigated the physiological effects of ICV Aβ40 peptide in a rat model of conditional 
hypertension (dependent on dietary salt intake). Aβ ICV infusion induced a progressive, highly 
significantly rise in BP in rats with pre-existing hypertension (high salt DAHL/SS) but no change in BP in 
rats that were normotensive (low salt DAHL/SS) prior to infusion. Our results suggest that Aβ has the 
potential to increase BP, particularly in the context of pre-existing hypertension. 
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The hypertension induced by Aβ may be a protective response to cerebral hypoperfusion. In a 
series of 259 normotensive and hypertensive adults, Warnert et al.14 found that hypertension was 
associated with vertebral artery hypoplasia, an incomplete posterior circle of Willis, increased cerebral 
vascular resistance and reduced cerebral blood flow. There is a substantial literature suggesting that Aβ 
increases cerebral vascular resistance and reduces cerebral blood flow. Topical application of Aβ40 to 
isolated arteries or to mouse cortex in vivo was shown to induce vasoconstriction.23, 36 In mice 
overexpressing mutant amyloid-β precursor protein (Tg2576), excess endogenous Aβ was shown to 
induce vasoconstriction and inhibit autoregulation and neurovascular coupling.20, 21, 23 Our results 
demonstrate the prolonged effects of long-term infusion with Aβ40 on BP, and differ somewhat from 
previous in vivo studies which had a short infusion period. For example, Sprague-Dawley rats given short-
term intra-arterial infusion of Aβ40 showed a substantial increase of MBP but only in hypotensive animals, 
with no change in normotensive animals. In the same study, vehicle infusion in spontaneously 
hypertensive animals induced a significant reduction in BP which was abolished by the infusion of Aβ40.51 
In another study, mice were given subcutaneous DOCA-salt implants to induce hypertension, followed by 
subcutaneous Aβ40 over 30-45 minutes; the increase in MBP was no different between animals that 
received Aβ40 and those given vehicle, but the former showed an attenuated response to ACh.52 
Aβ has multiple cerebrovascular effects that influence the regulation of CBF (for review see7, 9). 
Cerebral perfusion declines several years before the development of dementia, in both sporadic11 and 
familial AD,10 particularly in brain regions with early accumulation of Aβ,10 and this is associated with 
preclinical white matter damage (i.e. the fall in perfusion exceeds the decline in metabolic demand and 
causes tissue injury).12 Further evidence of a deficit in cerebral perfusion in AD comes from studies 
showing elevation of vascular endothelial growth factor, and significantly greater loss of the ischaemia-
sensitive myelin-associated glycoprotein (MAG) than the relatively resistant proteolipid protein-1 (PLP-
1).7-9, 53-55 Hypoxic alterations in brain tissue in early AD correlate closely with Aβ accumulation.9 Aβ 
accumulation also correlates with BBB leakage, indicating involvement of multiple components of the 
neurovascular unit in AD.56 There is a complex relationship between Aβ, BBB dysfunction and cerebral 
hypoperfusion, whereby BBB dysfunction reduces blood flow and impairs Aβ clearance,57, 58 and Aβ 
damages the BBB through pericytic57, 59, 60 and endothelial toxicity and increased monocyte adhesion.61 A 
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sustained reduction in cerebral blood flow might be expected to induce systemic hypertension, as a 
homeostatic response to restore blood flow by raising perfusion pressure. 29-31 
Aβ infusion had sustained or progressive effects on multiple cardiovascular control mechanisms, as 
evidenced by the changes in heart rate and blood pressure variability, and in baroreflex responsiveness. 
These physiological alterations were most marked in the hypertensive (high-salt) animals and included 
elevation of VLF, LF and HF components of SBPV but not significant alterations in HRV. The interpretation 
of and physiological basis for SBPV are somewhat contentious, but there is agreement that the LF and VLF 
components involve sympathetic supply to arteries.62 The physiological data suggest strongly that 
elevated sympathetic activity contributed to the increase in total peripheral resistance underling the 
hypertensive effects of Aβ. 
Both HRV and SBPV are altered in AD, with some changes evident before development of dementia. 
For example, patients with mild AD and MCI have altered HRV and SBPV in response to orthostatic 
stress.63 Lower cognitive performance was associated with altered HRV in AD, evidence of elevated 
cardiac sympathetic activity (LF:HF power ratio) and lower parasympathetic activity (HF power).64 
Increased SBPV variability (adjusted for raised SBP average itself and monitored over medium to long 
periods) is associated more generally with negative clinical outcomes, cardiovascular events, mortality 
and stroke.65 In a study of 25,000 people at high risk of cardiovascular disease, the risk of developing 
cognitive impairment was elevated in patients with greater variability of visit-to-visit BP, independent of 
the absolute BP itself.66 
Aβ infusion affected control of the baroreceptor reflex. This is also compromised in AD. Compared 
to age-matched control, AD patients had depressed baroreflex sensitivity.67 In a further study, baroreflex 
values were lower in AD than in controls or MCI, and differed significantly between MCI and controls.68 
These changes presumably reflect alterations (functional or structural) to brain regions involved in the 
baroreflex regulation of sympathetic activity, for example adrenaline-synthesizing medullary neurons 
(around 30% of which are lost in AD) and noradrenergic neurons in the locus coeruleus, affected by 
neurofibrillary tangles and neurodegeneration in early AD.64, 69 Baroreflex sensitivity in midlife has a 
positive association with regional perfusion to the hippocampus (hypoperfused in apparently healthy, 
middle-aged normotensive adults in whom baroreflex sensitivity is reduced).70 In older adults (65 ± 6 y) 
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with and without MCI, stiffness of central arteries and depressed baroreflex sensitivity correlated 
independently with white matter lesions.71  
Alterations to the activity of the sympathetic nervous system and baroreflex could be driving the 
hypertension observed in this study. Central administration of Aβ40 to the lateral ventricle may mediate 
the raised sympathetic activity and reduced BRG via NADPH oxidase-mediated production of reactive 
oxygen species (ROS) and/or downregulation of nitric oxide synthase (NOS). Oxidative stress plays a role 
in the generation and maintenance of arterial hypertension in human and several animal models, 
including the DAHL/SS rat. Oxidative stress in the brain is linked to hypertension pathogenesis via 
reductions to baroreflex sensitivity and activation of the sympathetic nervous system.72 The hypertensive 
effects of high-salt in DAHL/SS rats are partly mediated by increased activity of NADPH oxidase and the 
production of higher levels of ROS, and impaired vasodilation resulting from reduced activity of NOS. 
NADPH-derived ROS and associated reduction in bioavailability of nitric oxide probably contribute to the 
cerebrovascular dysfunction induced by Aβ.73 
We investigated two potential mechanisms whereby Aβ might have increased cerebral vascular 
resistance and induced hypertension: upregulation of EDN1 production and elevation of ACE activity. We 
did not find evidence of significant changes in either pathway but it is difficult to interpret these end-
stage analyses, as they were conducted after depletion of the Aβ infusate; according to the manufacturer, 
the delivery of infusate by the osmotic pumps is constant for approximately 28 d but then declines 
rapidly, and in keeping with this we found little residual Aβ40 in brain tissue homogenates after this 
period. It seems most likely that the peptide is cleared relatively quickly in this model. Rapid turnover of 
Aβ40 was previously demonstrated in APP transgenic mice, with a half-life of approximately 0.7 h for 
soluble, non-deposited forms of Aβ40.74 Limitations of the present study include the relatively small 
sample sizes for the measurements of some of the baroreflex and variability data, and our use of supra-
physiological levels of Aβ40 to model the effects of chronic Aβ-induced cerebral hypoperfusion but over a 
much shorter period than would apply in human Alzheimer's disease. In addition, we did not assess 
hypoperfusion by measurement of vascular endothelial growth factor or the MAG:PLP-1 ratio in this 
series of experiments but that would certainly be of interest in future studies.  
In conclusion, we have shown that ICV infusion of Aβ40 over a 4-week period alters autonomic 
control of cardiovascular function, causing progressive elevation in systemic blood pressure in rats with 
16 
 
pre-existing hypertension. These findings raise the possibility that (i) mid-life hypertension may, in some 
cases, be a physiological response to reduced cerebral perfusion complicating the accumulation of Aβ 
within the brain, and (ii) cerebral accumulation of Aβ may be particularly likely to exacerbate pre-existing 
hypertension.  
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Table 1 Pre-infusion baseline telemetry data 
 
 
Pre-infusion baseline telemetry data in high- and low-salt groups. Mean values ± SEM. *Weight prior to 
telemetry surgery at 12-14 weeks of age. Baseline MBP, SBP, DBP and RR were significantly higher in the 
high- than the low-salt group (1 = p < 0.0001, 2 = p < 0.05). (Key: MBP, SBP, DBP = mean, systolic and 















High Salt 12 361 ± 6 151 ± 6 1 169 ± 7 1 134 ± 5 1 373 ± 5 92 ± 4 2 
Low Salt 15 359 ± 9 114 ± 2 127 ± 2 103 ± 2 364 ± 4 82 ± 3 
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Legends to Figures 
Figure 1 Change in BP, HR and RR in High-Salt DAHL/SS 
Change in BP, HR and RR in high salt DAHL/SS over 28 d of Aβ (n=6) or saline (n=6) infusion. Each data 
point represents the group mean value on a given day during infusion. Best-fit linear regression (solid) 
and 95% CI (dotted) lines are shown. A comparison (sum-of-squares F-test) of best-fit regression lines 
tested the null hypothesis (H0) that a single linear regression line could fit the combined data sets for the 
change in HR, RR, MBP, SBP and DBP, relative to baseline, after infusion of Aβ or saline. H0 was rejected 
for each comparison. There was a highly significant greater effect of Aβ infusion compared to control 
(saline) infusion on (A) MBP (F2,288 = 38.45, p < 0.0001), (B) SBP (F2,288 = 61.50, p < 0.0001), (C) DBP (F2,288 
= 19.95, p < 0.0001), (D) HR (F2,288 = 23.94, p < 0.0001), (E) RR (F2,288 = 26.51, p < 0.0001). The increase in 
MBP, SBP and DBP was much greater in Aβ40- than saline-infused animals (P < 0.0001), and the decline in 
HR and RR less marked (P < 0.0001). 
Figure 2 Change in BP, HR and RR in Low-Salt DAHL/SS  
Change in (A) MBP, (B) SBP, (C) DBP, (D) HR and (E) RR in Aβ- (n=8) or saline-infused (n=7) DAHL/SS 
rats on low salt diet. A sum-of squares F-test comparison tested the null hypothesis (H0) that a single 
linear regression line could fit the combined data sets. H0 was accepted for MBP, SBP and DBP but 
rejected for HR and RR. There was no significant effect of Aβ infusion compared to control (saline) 
infusion on either MBP (F2,328 = 1.138, p > 0.05), SBP (F2,328 = 2.386, p > 0.05) or DBP (F2,328 = 0.632, ns). As 
the best-fit lines for blood pressure (MBP, SBP and DBP) did not differ significantly, a shared best-fit line 
is shown for the two infusion groups. There was a significant effect of Aβ infusion compared to control 
(saline) on both HR (F2,328 = 19.24, p < 0.0001) and RR (F2,325 = 11.59, p < 0.0001). Individual best-fit lines 
are shown for HR and RR.   
Figure 3 Change in HRV, SBPV and BRG in High-Salt DAHL/SS 
Change in HRV, SBPV and mean BRG in high salt DAHL/SS after Aβ (n=5) or saline (n=3) infusion. There 
were no significant effects of Aβ infusion on the (A) VLF (F2,148 = 0.120, ns) and (B) LF (F2,148 = 2.507, ns) 
components of HRV. There was a significant effect of Aβ infusion on (C) HF (F2,148 = 10.64, p < 0.0001). 
There was a significant effect of Aβ infusion on (D) VLF (F2,148 = 17.46, p < 0.0001), (E) LF (F2,148 = 15.59, p 
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< 0.0001), and (F) HF (F2,148 = 17.46, p < 0.0005) components of SBPV. There was a significant difference 
in the change in mean BRG (Mn.BRG) (G) positive (F2,202 = 28.91, p < 0.0001) and (H) negative (F2,202 = 
4.761, p < 0.001) ramps during Aβ compared with saline infusion. Data are presented as daily group 
means, with lines of best-fit (solid) and 95% CI (dotted). A combined best-fit line is shown for both 
infusion groups when the H0 was accepted (A-B). Separate lines for Aβ- and saline- infusion groups are 




















Supplementary Figure Legends 
Supplementary Figure 1 
Change in BP, HR and RR in high-salt DAHL/SS relative to baseline (day -7 to 0) after either Aβ (n=6) or 
saline (n=6) infusion (post-infusion data from day 3 to 28). Each data point represents the individual 
mean value over a given 24-h period, adjusted to the baseline mean value for the same individual.  
Supplementary Figure 2 
Change in BP, HR and RR in low-salt DAHL/SS relative to baseline (day -7 to 0) after either Aβ (n=8) or 
saline (n=7) infusion (post-infusion data from day 3 to 28). Linked scatter plots represent data points for 
the individual mean value on a given 24-h period, adjusted to the baseline mean value for the same 
individual.  
Supplementary Figure 3 
Change in HRV, SBPV and mean BRG in high-salt DAHL/SS relative to baseline (day -7 to 0) after Aβ (n=5) 
or saline (n=3) infusion (post-infusion data from day 3 to 28). Linked scatter plots represent data points 
for the individual mean value on a given 24h period, adjusted to the baseline mean value for the same 
individual.  
Supplementary Figure 4  
MBP in high- and low-salt DAHL/SS following Aβ-/saline-infusion. A paired t-test was used to compare 
MBP in the final week following infusion (day 22-28 inclusive) relative to pre-infusion baseline. MBP in 
(A) low-salt DAHL/SS increased after Aβ infusion (day 22-28 vs. baseline) by 3 ± 3 mmHg (t (7) = 2.948, p 
= 0.022), but did not change significantly after (B) saline infusion. MBP in the (C) high-salt DAHL/SS 
increased by 21 ± 11 mmHg (mean ± SD) in the Aβ group (t (5) = 4.726, p = 0.005), whereas MBP in the 
(D) saline group increased by 11 ± 8 mmHg (t (5) = 3.635, p = 0.015).  
Supplementary Figure 5  
Aβ40, ET-1, ECE-1, ECE-2 levels and ACE activity in high- and low-salt DAHL/SS after Aβ or saline infusion. 
No significant difference was found in Aβ40 level in the high- or low- salt DAHL/SS after 4 weeks' Aβ-
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infusion in (A) brain tissue homogenates (mean + SD). In (B) plasma samples, Aβ40 levels were lower than 
in brain tissue homogenates and several cases fell below the detection limit of the assay; no significant 
difference was found in the Aβ40- compared with saline-infused high- or low-salt DAHL/SS (median + IQR 
shown as data skewed to left). No significant differences were found in the levels of EDN1, ECE-1 or ECE-2 
in brain tissue homogenates. Mean + SD of total (C) EDN1 (pg/ml) (D) ECE-1+ECE-1sv (pg/ml) (E) ECE-2 
(ng/ml) are shown, presented as mean results from left and right-brain homogenates combined.  ACE 
activity in high and low salt DAHL/SS in (F) brain tissue homogenates; (G) plasma. No significant 
difference was found between Aβ-infused brain tissue homogenates with respect to ACE activity. 
Supplementary Figure 6 
Example power spectral components and time series data for variability and baroreflex sensitivity 
analyses. HR and SBP waveforms were analysed by use of Spike2 with the HRV1.s2s script, with a (A) 60-s 
epoch duration shown. A SPBV power spectrum example (B) is shown for the 60-s period above, with the 
vertical lines to indicate the low and high edges of the frequency bands analysed (VLF 0-0.26 Hz; LF 0.26-
0.76 Hz; HF 0.76-3.3 Hz). An example results table (C) is also shown. Baroreflex sensitivity was analysed 
by use of Spike2 software running the sBRG.s2s script, reflecting spontaneous fluctuations in BP and 
pulse interval. (D) a smoothed BP and pulse interval trace is generated, and ramps are marked during 
which BP rises or falls consistently over several heartbeats. (E) Example plot of a positive ramp (R+), and 
(F) of a negative ramp (R-) show the blood pressure vs. changes in pulse interval after 3, 4, and 5 
heartbeats. The baroreceptor reflex sensitivity was estimated from the linear best fit of this correlation. 
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